Drug intelligence / Profile preview

Magic Mouthwash + sucralfate

Development stage: Unknown
Lead developer: Vanderbilt-Ingram Cancer Center
Modality: Small Molecules
Administration: Oral

Overview

Magic Mouthwash + sucralfate is a combination treatment used primarily for the prevention and management of radiation-induced oral mucositis, particularly in patients receiving radiotherapy for head and neck cancer. Magic mouthwash typically contains a mixture of medications such as diphenhydramine (an antihistamine), dexamethasone (a steroid), and nystatin (an antifungal), while sucralfate is an oral gastrointestinal medication that forms a protective coating over mouth sores. The combination is used to reduce inflammation, pain, and discomfort associated with oral mucositis.

Other names: MM+S

Targets

GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Magic Mouthwash + sucralfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magic Mouthwash + sucralfate.

Explore the full profile